Logo image of SLRX

SALARIUS PHARMACEUTICALS INC (SLRX) Stock Fundamental Analysis

NASDAQ:SLRX - US79400X4043 - Common Stock

5.43 USD
-0.33 (-5.73%)
Last: 9/2/2025, 11:28:57 AM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to SLRX. SLRX was compared to 542 industry peers in the Biotechnology industry. Both the profitability and financial health of SLRX have multiple concerns. SLRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SLRX had negative earnings in the past year.
SLRX had a negative operating cash flow in the past year.
In the past 5 years SLRX always reported negative net income.
SLRX had a negative operating cash flow in each of the past 5 years.
SLRX Yearly Net Income VS EBIT VS OCF VS FCFSLRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

SLRX has a Return On Assets of -366.41%. This is amonst the worse of the industry: SLRX underperforms 94.83% of its industry peers.
Industry RankSector Rank
ROA -366.41%
ROE N/A
ROIC N/A
ROA(3y)-196.87%
ROA(5y)-130.59%
ROE(3y)-303.46%
ROE(5y)-195.66%
ROIC(3y)N/A
ROIC(5y)N/A
SLRX Yearly ROA, ROE, ROICSLRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLRX Yearly Profit, Operating, Gross MarginsSLRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for SLRX has been increased compared to 1 year ago.
The number of shares outstanding for SLRX has been increased compared to 5 years ago.
SLRX has a worse debt/assets ratio than last year.
SLRX Yearly Shares OutstandingSLRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K
SLRX Yearly Total Debt VS Total AssetsSLRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -97.25, we must say that SLRX is in the distress zone and has some risk of bankruptcy.
SLRX's Altman-Z score of -97.25 is on the low side compared to the rest of the industry. SLRX is outperformed by 95.76% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -97.25
ROIC/WACCN/A
WACCN/A
SLRX Yearly LT Debt VS Equity VS FCFSLRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 0.61 indicates that SLRX may have some problems paying its short term obligations.
SLRX has a Current ratio of 0.61. This is amonst the worse of the industry: SLRX underperforms 92.25% of its industry peers.
A Quick Ratio of 0.61 indicates that SLRX may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.61, SLRX is doing worse than 91.70% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.61
Quick Ratio 0.61
SLRX Yearly Current Assets VS Current LiabilitesSLRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

0

3. Growth

3.1 Past

SLRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.28%, which is quite impressive.
EPS 1Y (TTM)74.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SLRX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.17% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-126.98%
EPS Next 2Y-3.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLRX Yearly Revenue VS EstimatesSLRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2026 2M 4M 6M 8M 10M
SLRX Yearly EPS VS EstimatesSLRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 -2K -4K -6K -8K -10K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLRX. In the last year negative earnings were reported.
Also next year SLRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLRX Price Earnings VS Forward Price EarningsSLRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLRX Per share dataSLRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -10 -20 -30 -40

4.3 Compensation for Growth

SLRX's earnings are expected to decrease with -3.17% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.17%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SLRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SALARIUS PHARMACEUTICALS INC

NASDAQ:SLRX (9/2/2025, 11:28:57 AM)

5.43

-0.33 (-5.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners3.29%
Inst Owner Change32.32%
Ins Owners1.71%
Ins Owner Change0%
Market Cap2.77M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short Ratio0.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-48.74
EYN/A
EPS(NY)-4.39
Fwd EYN/A
FCF(TTM)-8.12
FCFYN/A
OCF(TTM)-8.12
OCFYN/A
SpS0
BVpS-1.63
TBVpS-1.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -366.41%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-196.87%
ROA(5y)-130.59%
ROE(3y)-303.46%
ROE(5y)-195.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.61
Quick Ratio 0.61
Altman-Z -97.25
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.98%
EPS Next Y-126.98%
EPS Next 2Y-3.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.03%
OCF growth 3YN/A
OCF growth 5YN/A